DE60308654D1 - Ermittlung der auswirkung von einem clostridial toxin auf muskeln - Google Patents

Ermittlung der auswirkung von einem clostridial toxin auf muskeln

Info

Publication number
DE60308654D1
DE60308654D1 DE60308654T DE60308654T DE60308654D1 DE 60308654 D1 DE60308654 D1 DE 60308654D1 DE 60308654 T DE60308654 T DE 60308654T DE 60308654 T DE60308654 T DE 60308654T DE 60308654 D1 DE60308654 D1 DE 60308654D1
Authority
DE
Germany
Prior art keywords
clostridial toxin
muscles
identifying
impact
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60308654T
Other languages
English (en)
Other versions
DE60308654T2 (de
Inventor
D Hanin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28039639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60308654(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE60308654D1 publication Critical patent/DE60308654D1/de
Application granted granted Critical
Publication of DE60308654T2 publication Critical patent/DE60308654T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
DE60308654T 2002-03-14 2003-03-07 Ermittlung der Auswirkung von einem Clostridial-Toxin auf Muskeln Expired - Lifetime DE60308654T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99602 2002-03-14
US10/099,602 US6688311B2 (en) 2002-03-14 2002-03-14 Method for determining effect of a clostridial toxin upon a muscle
PCT/US2003/006779 WO2003077954A1 (en) 2002-03-14 2003-03-07 Method for determining effect of a clostridial toxin upon a muscle

Publications (2)

Publication Number Publication Date
DE60308654D1 true DE60308654D1 (de) 2006-11-09
DE60308654T2 DE60308654T2 (de) 2007-08-23

Family

ID=28039639

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60308654T Expired - Lifetime DE60308654T2 (de) 2002-03-14 2003-03-07 Ermittlung der Auswirkung von einem Clostridial-Toxin auf Muskeln

Country Status (10)

Country Link
US (2) US6688311B2 (de)
EP (1) EP1482986B1 (de)
JP (3) JP2005520826A (de)
KR (1) KR100963798B1 (de)
AT (1) ATE340593T1 (de)
AU (1) AU2003224657A1 (de)
CA (1) CA2478762A1 (de)
DE (1) DE60308654T2 (de)
ES (1) ES2272975T3 (de)
WO (1) WO2003077954A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
JP2007505423A (ja) * 2003-06-12 2007-03-08 コントロール バイオニクス 対話型の通信のための方法、システム、ソフトウェア、および解析
US7101742B2 (en) 2003-08-12 2006-09-05 Taiwan Semiconductor Manufacturing Company, Ltd. Strained channel complementary field-effect transistors and methods of manufacture
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
LT2985039T (lt) * 2004-03-03 2018-11-12 Revance Therapeutics, Inc. Botulino toksinų vietinis taikymas ir jų įvedimas per odą
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US8996603B2 (en) * 2004-09-16 2015-03-31 Cisco Technology, Inc. Method and apparatus for user domain based white lists
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
JP2008531732A (ja) 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
US20060276720A1 (en) * 2005-06-03 2006-12-07 Mcginnis William C Method of using dermatomal somatosensory evoked potentials in real-time for surgical and clinical management
JP4763347B2 (ja) * 2005-06-03 2011-08-31 ポーラ化成工業株式会社 マッサージ方法又はマッサージ料の評価方法
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
BRPI0619134B8 (pt) 2005-12-01 2021-05-25 Univ Massachusetts Lowell nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão
US7593769B1 (en) * 2006-02-14 2009-09-22 Iq Biolabs, Inc. Surface electromyography index
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
AU2007329579A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
AU2007353340A1 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
KR20090096735A (ko) * 2006-12-29 2009-09-14 레반스 테라퓨틱스, 아이엔씨. Ｈｉｖ-ｔａｔ로부터 유래된 폴리펩티드 단편에 의해 안정화된 보툴리눔 독소의 국소 적용 및 경피 전달용 조성물 및 방법
WO2008082885A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
CN103961315A (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
DE102008032021A1 (de) * 2008-07-07 2010-01-21 Proebstle, Thomas, Dr. Verfahren zum quantitativen Analysieren der Wirkung eines Effektors auf die mit Muskelkontraktion assoziierte Motilität der Haut
US8126542B2 (en) * 2008-12-10 2012-02-28 Somaxis, Inc. Methods for performing physiological stress tests
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
RU2458627C1 (ru) * 2011-04-05 2012-08-20 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Способ количественной оценки спастичности при центральном парезе
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
MX2014009083A (es) * 2012-01-27 2015-07-17 Revance Therapeutics Inc Metodos y escalas de evaluacion para la medicion de la gravedad de las arrugas.
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
JP2019122655A (ja) * 2018-01-18 2019-07-25 パシフィックメディコ株式会社 筋電位取得装置
US11752335B1 (en) 2018-02-07 2023-09-12 Mary Kay Inc. Method for determining facial muscle responses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689668A (en) * 1967-10-18 1972-09-05 Emile Leon Piette Method of alleviating wrinkles on skin
FR2589242B1 (fr) * 1985-10-25 1988-11-25 Oreal Procede pour examiner la surface d'un echantillon et appareil pour sa mise en oeuvre
AT391998B (de) * 1987-02-02 1990-12-27 Falko Dr Skrabal Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
GB8806737D0 (en) * 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5211894A (en) * 1990-10-09 1993-05-18 Amway Corporation Skin replication technique
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DK0758900T3 (da) 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
US5595740A (en) 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US5898545A (en) * 1997-07-01 1999-04-27 International Business Machines Corporation Head load/unload and disk airflow control apparatus
PT1011695E (pt) 1997-07-15 2006-07-31 Univ Colorado Utilizacao de terapia com neurotoxina para tratamento de doencas da prostata
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
AU1706400A (en) 1998-10-27 2000-05-15 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
EP1135094B1 (de) 1999-04-16 2009-03-11 Marvin Schwartz Verfahren zur verminderung des haarausfalls und förderung des haarwiederwachstums
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle

Also Published As

Publication number Publication date
KR100963798B1 (ko) 2010-06-17
KR20040093145A (ko) 2004-11-04
WO2003077954A1 (en) 2003-09-25
US20030178029A1 (en) 2003-09-25
ATE340593T1 (de) 2006-10-15
EP1482986A1 (de) 2004-12-08
AU2003224657A1 (en) 2003-09-29
JP2005520826A (ja) 2005-07-14
US7234469B2 (en) 2007-06-26
JP2013144711A (ja) 2013-07-25
US6688311B2 (en) 2004-02-10
EP1482986B1 (de) 2006-09-27
ES2272975T3 (es) 2007-05-01
US20040060569A1 (en) 2004-04-01
DE60308654T2 (de) 2007-08-23
JP2010106026A (ja) 2010-05-13
CA2478762A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
DE60308654D1 (de) Ermittlung der auswirkung von einem clostridial toxin auf muskeln
WO2006033800A3 (en) System and method of automaticallymodifying an online dating service search using compatibility feedback
WO2003025689A3 (en) Large scale process control by driving factor identification
ATE449168T1 (de) Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
HRP20060151A2 (en) The method of safe certification service
ATE391951T1 (de) Verfahren und vorrichtung zum authentifizieren von benutzern und websites
ATE433124T1 (de) System und verfahren zum analysieren von radarinformationen
WO2004031911A3 (en) Methods and apparatus to present survey information
WO2004075078A3 (en) Method and apparatus for fundamental operations on token sequences: computing similarity, extracting term values, and searching efficiently
WO2005059678A3 (en) System and method for providing identification and search information
BR9506217A (pt) Processo para identificação de estradas manuscritas e processo para determinar se dois segmentos contínuos pertencem a entradas manuscritas separadas
WO2003057648A3 (fr) Procedes et systemes de recherche et d'association de ressources d'information telles que des pages web
WO2003102764A3 (en) Behavior-based adaptation of computer systems
DE602007008805D1 (de) Verbindungsanpassung in Abhängigkeit von der Kontrollsignalisierung
NO20053316L (no) Fremgangsmate for marin seismisk innsamling, samt apparat.
WO2005024631A3 (en) Creating and checking runtime data types
EP1324251A3 (de) Verfahren und System zur Schätzung der Umweltbelastung
WO2006113799A3 (en) Planning method and system for use in cognitive programs
WO2005048108A3 (en) System, method, and computer program product for testing program code
DE60302631D1 (de) System und Verfahren zum Verteilen von kryptographischen Schlüsseln, Zugangspunkt und System zum Verteilen eines Authentifizierungskodes
DE50211145D1 (de) Detektion von wechselwirkungen auf sonden-arrays
DK0914605T3 (da) Molekylemodel for VLA-4-inhibitorer
ATE501470T1 (de) Verfahren und computer zur planung von versuchen
WO2001021839A3 (en) Gene expression profiles
DE602004027086D1 (de) Klassifizierung von kolonkrebs

Legal Events

Date Code Title Description
8363 Opposition against the patent